| Description | Purified Native Human Alpha 1 Antitrypsin, Human PlasmaBulk Qty Available.An acute-phase plasma protein found at 95-350 mg per 100 ml that functions as a protease inhibitor. Clinically, its deficiency is associated with two major diseases: pulmonary emphysema and early onset/juvenile hepatic Purified Native Human Alpha 1 Antitrypsin, Human PlasmaBulk Qty Available.An acute-phase plasma protein found at 95-350 mg per 100 ml that functions as a protease inhibitor. Clinically, its deficiency is associated with two major diseases: pulmonary emphysema and early onset/juvenile hepatic cirrhosis. It is elevated in inflammatory conditions, malignancies, liver disease and pregnancy and also after surgical trauma and use of oral contraceptives. The simultaneous quantitative determination of alpha-1-PI and ceruloplasmin permits differential diagnosis of liver afflictions.Activity: When tested with active-site titrated porcine pancreatic trypsin using Na-Benzoyl-L-Arginine-para-Nitroanilide Hydrochloride (L-BAPNA) as substrate, it is 75-100% inhibitory.Prepared from plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.For research use or for use in further manufacturing... Read More | Lipoprotein Lipase Activator is a cell-permeable benzylphosphonate derivative that selectively induces lipoprotein lipase (LPL) mRNA and protein levels, but does not exhibit PPARα or PPARγ agonistic activities. Lipoprotein Lipase Activator lowers serum lipid levels and plasma triglyceridesLipoprotein Lipase Activator is a cell-permeable benzylphosphonate derivative that selectively induces lipoprotein lipase (LPL) mRNA and protein levels, but does not exhibit PPARα or PPARγ agonistic activities. Lipoprotein Lipase Activator lowers serum lipid levels and plasma triglycerides with concomitant elevation in high-density lipoprotein cholesterol (HDL-C) in animal models. Lipoprotein Lipase Activator also induces fatty acid oxidation related enzymes, lowers free fatty acids (FFA), and minimizes fat accumulation. Also reported to suppress the plasma levels of TNF-a and COX-2 and displays anti-tumor properties... Read More | Purity:>95%, by SDS-PAGE visualized with Coomassie® Blue Staining.Description:GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) is a Protein Coding gene. Diseases associated with GAPDH include Microcephaly 21, Primary, Autosomal Recessive and Schistosomiasis. Among its related pathways are Purity:>95%, by SDS-PAGE visualized with Coomassie® Blue Staining.Description:GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) is a Protein Coding gene. Diseases associated with GAPDH include Microcephaly 21, Primary, Autosomal Recessive and Schistosomiasis. Among its related pathways are glycolysis (BioCyc) and gluconeogenesis III. Gene Ontology (GO) annotations related to this gene include identical protein binding and NAD binding. An important paralog of this gene is GAPDHS... Read More | Inquire | Purity≥95% SDS-PAGE. Recombinant human MIF, fused to His-tag at N-terminus, was cloned into an E. coli expression vector and was purified to apparent homogeneity by using conventional column chromatography techniques.FunctionPro-inflammatory cytokine. Involved in the innate immune response to Purity≥95% SDS-PAGE. Recombinant human MIF, fused to His-tag at N-terminus, was cloned into an E. coli expression vector and was purified to apparent homogeneity by using conventional column chromatography techniques.FunctionPro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity... Read More |